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Abstract
Machado–Joseph disease (MJD) is a neurodegenerative disorder caused by an abnormal expansion of
citosine-adenine-guanine trinucleotide repeats in the disease-causing gene. This mutation leads to an abnormal
polyglutamine tract in the protein ataxin-3 (Atx3), resulting in formation of mutant Atx3 aggregates. Despite several
attempts to develop a therapeutic option for MJD, currently there are no available therapies capable of delaying or stopping
disease progression. Recently, our group reported that reducing the expression levels of mutant Atx3 lead to a mitigation of
several MJD-related behavior and neuropathological abnormalities. Aiming a more rapid translation to the human clinics, in
this study we investigate a pharmacological inhibitor of translation—cordycepin—in several preclinical models. We found
that cordycepin treatment significantly reduced (i) the levels of mutant Atx3, (ii) the neuropathological abnormalities in a
lentiviral mouse model, (iii) the motor and neuropathological deficits in a transgenic mouse model and (iv) the number of
ubiquitin aggregates in a human neural model. We hypothesize that the effect of cordycepin is mediated by the increase of
phosphorylated adenosine monophosphate-activated protein kinase (AMPK) levels, which is accompanied by a reduction in
the global translation levels and by a significant activation of the autophagy pathway. Overall, this study suggests that
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Introduction
Machado–Joseph disease (MJD), or spinocerebellar ataxia type 3,
is an autosomal dominantly inherited neurodegenerative dis-
order. It belongs to the polyglutamine (polyQ) diseases group,
which is caused by consecutive repetitions of the trinucleotide
citosine-adenine-guanine in the coding region of the disease-
causing genes, translating to a pathogenic polyQ tract in the
corresponding proteins (7). Regarding MJD, the causative gene is
MJD1 and the mutated protein is ataxin-3 (Atx3), a deubiquiti-
nating enzyme which is thought to play a role in the ubiquitin-
mediated proteolysis (9). In a normal situation, Atx3 contains
10–51 glutamines, while when mutated this protein carries 55–
84 glutamines (12). The polyQ tract in Atx3 induces protein
aggregation and accumulation of insoluble ubiquitin-positive
aggregates of mutant Atx3 inside neuronal cells, leading to pro-
gressive neurodegeneration in several brain regions, including
the cerebellum, substantia nigra and spinal cord (28). This severe
neuropathological phenotype results in numerous symptoms,
such as progressive ataxia, dysphagia, dysarthria and rigidity
among others (32). Currently, there is no effective treatment to
delay or stop disease progression.
In the past years, several therapeutic approaches were stud-
ied in different preclinical models, such as RNA interference-
based strategies (1,20), the activation of protein clearance
systems (15) or stem cells transplantation (13). However, none
of these strategies were yet translated to human application.
Therefore, there is an urgent need to develop therapeutic
strategies for MJD and for the other polyQ diseases, which could
be easily translated to the clinics.
Cordycepin or 3′-deoxyadenosine is a bioactive compound
found in the fungi Cordyceps and a derivative of the nucleoside
adenosine (22). It was suggested that cordycepin might activate
the adenosine monophosphate-activated protein kinase (AMPK)
pathway, thus reducing protein translation levels (31). Recently,
we reported that ataxin-2 overexpression reduced the expres-
sion levels of mutant Atx3, through the reduction of the Atx3
translation (17). Thus, we suggested that targeting mutant Atx3
translation could be a potential therapeutic strategy for MJD, as
it resulted in alleviation of the severe phenotype observed in dif-
ferent preclinical models. Nevertheless, the modulation of trans-
lation levels was achieved by a lentiviral-based therapy, which is
still far away to be used in a clinical context. Thus, in this study
we aimed at investigating a pharmacological treatment based
in the administration of cordycepin in several MJD preclinical
models, as well as to characterize its molecular mechanism of
action. We observed that cordycepin administration decreased
the levels of mutant Atx3 aggregates in in vitro and in vivo models,
resulting in the amelioration of the associated abnormalities
of lentiviral and transgenic mouse models. Furthermore, we
reported that this cordycepin effect is mediated by activation
of AMPK pathway, independently of the mammalian target of
rapamycin (mTOR) pathway, resulting in the reduction of the
global translation levels and in a significant activation of the
autophagy pathway. Overall, this study suggested for the first
time that cordycepin might constitute a therapeutic approach
for MJD, and probably to other polyQ diseases.
Results
Cordycepin treatment reduces the mutant Atx3 levels
in N2A cells
Previously, we reported that the molecular regulation of mutant
Atx3 translation resulted in alleviation of the MJD phenotype
(17). In line with these results, we found that cordycepin (transla-
tion inhibitor) treatment decreased mutant Atx3 (72Q) levels in a
mouse neuroblastoma cell line (N2A cells) model (Fig. 1A and C),
whereas no alterations were detected in mouse endogenous
Atx3 (Fig. 1A–B, 1D) or in human wild-type Atx3 (27Q) levels
(Fig. 1B and E).
Figure 1. Cordycepin decreases the levels of mutant Atx3 in N2A cells. Western blot of protein lysates from N2A cells expressing human full-length mutant Atx3Q72 (A)
and human wild-type Atx3 with 27 glutamines (B) treated with 20 μm cordycepin for 48 h and non-treated (control) (n = 4 independent experiments). The cordycepin
treatment decreased the levels of mutant Atx3 compared to control levels (C), whereas mouse endogenous Atx3 remained unaltered (D) as well as wild-type Atx3 protein
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Figure 2. Cordycepin induces AMPK activation promoting autophagy in N2A cells. (A) Western blot of protein lysates from N2A cells treated with 20 μm cordycepin
for 48 h and non-treated (control) (n = 6 independent experiments). (B) The treatment with cordycepin led to a significant increase in the levels of P-AMPK relative to
total AMPK levels when compared to control, suggesting an activation of AMPK signaling pathway. Western blot analysis of LC3B-II (C) and SQSTM1 (D) levels (n = 3
independent experiments). Cordycepin treatment decreased the levels of LC3B-II (E) and SQSTM1 (G), while an accumulation of these subtracts was detected in the
presence of ChQ. (F) LC3B-II net flux was calculated by subtracting the amount of LC3B-II in treated condition from the condition treated with ChQ. Cordycepin induced
an increase in LC3B-II net flux compared to control levels, suggesting an activation of the autophagic flux. Western blot analysis of P-mTOR and mTOR (H) and P-ULK1–
Ser555 and ULK1 (I) levels (n = 4 independent experiments). Cordycepin treatment resulted in a significant increase of the P-mTOR relative to total mTOR levels (J) and
in a significant decrease in P-ULK1 relative to total ULK1 levels (K). Values are expressed as mean ± SEM. ∗P < 0.05, ∗∗P < 0.01; ∗∗∗P < 0.001 (one-way ANOVA relative to
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Cordycepin activates AMPK, increasing its
phosphorylation, inducing autophagy and reducing
overall translation levels in N2A cells
Next, we tried to elucidate the molecular mechanism behind the
cordycepin effect in reducing mutant Atx3 levels. Previously, it
was hypothesized that cordycepin inhibits translation through
activation of AMPK pathway (31). In line with this, we found that
cordycepin significantly increased the levels of phosphorylated
AMPK (P-AMPK) in N2A cells expressing human full-length
mutant Atx3 (Fig. 2A and B). This increase was accompanied
by a significant decrease in the global protein synthesis levels
(Supplementary Material, Fig. 1). These results raised the hypoth-
esis that cordycepin might also impact autophagy induced
by AMPK activation (11). In line with this, we next assessed
the levels of two autophagic markers, LC3B-II (Fig. 2C) and
sequestosome-1 (SQSTM1; Fig. 2D). After cordycepin treatment,
we observed a decrease in both LC3B-II (Fig. 2C and E) and
SQSTM1 protein levels (Fig. 2D and G), suggesting an increase
of autophagic clearance. To confirm that cordycepin was, in
fact, enhancing autophagy, we evaluated LC3B-II and SQSTM1
levels in the absence and presence of chloroquine (ChQ), an
inhibitor of autolysosomal degradation. In the presence of
ChQ, both LC3B-II and SQSTM1 accumulate upon cordycepin
treatment (Fig. 2C and D). In addition, when comparing the
differences in the amount of LC3B-II between samples in the
presence and absence of ChQ (autophagic flux), we observed that
cordycepin significantly increased autophagic flux in N2A cells,
expressing human full-length mutant Atx3 (Fig. 2F). Altogether,
these results demonstrate that cordycepin activates autophagy.
To further investigate the impact of cordycepin in autophagy
activation, we next studied the mTOR, a negative regulator of
autophagy (3) and UNC-51-like autophagy activating kinase
1 (ULK1), an autophagy activating enzyme levels. We found
that cordycepin treatment significantly increased the levels
of phosphorylated mTOR (P-mTOR) (Fig. 2H and J), whereas a
Figure 3. Cordycepin reduces mutant Atx3 levels in a lentiviral MJD mouse model through the activation of autophagy. (A) Schematic representation of the stereotaxic
injection of LV encoding for mutant Atx3Q72 in the right hemisphere of the striatum (B). Timeline of the experiment; the animals received the LV injection at 8 weeks
old and cordycepin treatment started one week later. Treated animals (n = 3) were administered with a daily intraperitoneal injection of 20 mg/Kg of cordycepin-
NaCl 0.1%, whereas control group (n = 3) received the vehicle (NaCl 0.1%) during 1 week. Western blot analysis of Atx3 protein (C) and LC3B-II and SQSTM1 proteins
(F) of striatal punches of animals’ brain. Cordycepin treatment significantly decreases the levels of Atx3 aggregates (D) and soluble mutant Atx3 (E). Cordycepin
administration resulted in a significant increase in LC3B-II autophagic marker (G) as well as a reduction of SQSTM1 autophagic protein (H), thus suggesting an activation
of autophagy. Results were expressed as mutant Atx3 aggregates or soluble protein over tubulin levels and as LC3B-II or SQSTM1 over GADPH levels. Values are expressed
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Figure 4. Cordycepin mitigates neuropathological deficits and reduces mutant Atx3 levels in a lentiviral MJD mouse model. (A) Schematic representation of a stereotaxic
injection of LV encoding for mutant Atx3Q72 in the right hemisphere of the striatum (B). Timeline of the experiment; the animals received the LV injection at 8 weeks
old and cordycepin treatment started one week later. Treated animals (n = 9) were administered a daily intraperitoneal injection of 20 mg/Kg of cordycepin-NaCl 0.1%,
whereas control group (n = 9) received the vehicle (NaCl 0.1%). Treatment was prolonged for 4 weeks. (C, D, F, G) Immunohistochemistry staining for ubiquitin depicting
mutant Atx3 aggregates. Animals treated with cordycepin (n = 4) showed a significant decrease in the number (E) as well as the size (H) of the inclusions compared to
control group (n = 4). (I, J) Immunohistochemistry staining for the neuronal marker NeuN. (K) Cordycepin treatment (n = 4) resulted in a preservation of NeuN staining
volume compared to non-treated condition (n = 4). Results were expressed as NeuN-depleted volume relative to total striatum volume. (L) Western blot of striatal
punches of the lentiviral model (n = 5 for both groups). The cordycepin treatment reduced the levels of mutant Atx3 aggregates (M) and mutant soluble Atx3 protein
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Figure 5. Cordycepin ameliorates motor performance and neuropathology in a transgenic MJD mouse model. (A–D) Behavioral assessment of the animals started
before the treatment (0 weeks) and it was performed every 2 weeks until the end of the experiment (6 weeks). Animal motor coordination and balance were evaluated
through constant (A) and accelerated rotarod tests (B). Mice treated with cordycepin (n = 10) stayed for long in the rotating rod at 6 weeks (A) post-injection for constant
speed and at 5 and 6 weeks for increased velocity (B), compared to non-treated animals (n = 8). The results were normalized to the control average for each time point.
Values are presented as mean ± SEM. ∗P < 0.05, ∗∗P < 0.01 (two-way ANOVA). Cordycepin treatment (n = 10) showed a decrease in footprint overlap (C) and a significant
decrease in hind base width measures (D) compared to control condition (n = 8). (E–J) Representative fluorescence microscopy images detailing DAPI, calbindin and
HA staining’s for cordycepin treated animals (H–J) and control group (E–G). Arrowheads point towards cells with HA aggregates. Administration of cordycepin led to a
robust decrease in the number of cells with mutant Atx3 aggregates in the cerebellum (K). (L–O) Representative fluorescence microscopy images of calbindin staining
for mice treated with cordycepin (M, O) and non-treated group (L, N). Results showed a significant increase of Purkinje cells in the treated group compared to control
animals (P). Representative microscopy images of cresyl violet histological staining for treated group (R) and non-treated mice (Q). Cordycepin treatment resulted in
a significant decrease in cerebellar lobe 7 volume compared to non-treated animals (S). Results are expressed as lobe 7 volume relative to cerebellum total volume.
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significant reduction in phosphorylated ULK1 at Ser555 (P-ULK1–
Ser555) levels (Fig. 2I and K) was observed. Altogether, these
results suggest that cordycepin leads to a strong activation of
autophagy through mTOR-independent pathway.
Cordycepin reduces mutant Atx3 protein levels
through activation of autophagy in a lentiviral MJD
mouse model
After the in vitro validation of cordycepin treatment, we next
aimed at investigating whether this compound could reduce
the levels of mutant Atx3 in a lentiviral mouse model of MJD.
For that, animals were injected, in the right hemisphere of the
striatum, with lentiviral vectors (LVs) encoding for mutant Atx3
with 72 glutamines (Atx3Q72) (Fig. 3A). Cordycepin intraperi-
toneal injections (IP) were administered daily for 1 week, starting
1 week post-LV injection (Fig. 3B). Western blot analysis of brain
striatal punches (Fig. 3C) showed that cordycepin treatment led
to a significant decrease of both mutant Atx3 aggregates (Fig. 3D)
and soluble mutant Atx3 (Fig. 3E) levels compared to the control
group, treated with saline solution. Moreover, we assessed the
levels of LC3B-II and SQSTM1 (Fig. 3F) and observed that cordy-
cepin treatment significantly increases LC3B-II levels (Fig. 3G)
and reduced SQSTM1 levels (Fig. 3H), which is line with studies
using pharmacological agents to induce autophagy in vivo and
thus suggesting that cordycepin might be activating autophagy
in vivo (14). These results indicate that cordycepin can effectively
reduce mutant Atx3 levels in an in vivo MJD model through
activation of the autophagic pathway.
Figure 6. Cordycepin decreases the number of ubiquitin aggregates in a human neural MJD model. Immunocytochemistry staining for ubiquitin (B, E) and tubulin
proteins (A, D). Arrowheads point toward ubiquitinated inclusions and arrows point to cells containing aggregates. Cordycepin treatment (n = 4) decreased the number
of ubiquitin-positive aggregates in treated cells compared to non-treated cells (G). (H) Analysis of cell viability through the resazurin reduction assay. Cordycepin
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Cordycepin treatment ameliorates mutant
Atx3-induced abnormalities in a lentiviral MJD
mouse model
The in vivo expression of mutant Atx3 mediated by LV leads to
the formation of ubiquitinated aggregates (which are a hallmark
of MJD) and the loss of neuronal markers in the striatum and
cerebellum (2,18). We next administered a cordycepin treat-
ment in a MJD striatal lentiviral model (Fig. 4A) for 4 weeks,
with daily administered IP injections (Fig. 4B). The cordycepin
treatment led a significant decrease in the total number of
ubiquitinated aggregates (Fig. 4C–E), in the size of the aggre-
gates (Fig. 4F–H) and to a significant preservation of the neu-
ronal marker NeuN (Fig. 4I and K, Supplementary Material, Fig.
2A–B), compared with the control animals treated with saline
solution. Moreover, we also observed that cordycepin treatment
reduced the mutant Atx3 protein aggregates and soluble levels,
detected by western blot (Fig. 4L–N). To evaluate a possible sys-
temic toxicity effect due to the cordycepin treatment, we ana-
lyzed the levels of liver enzymes in the blood of treated and non-
treated mice. Along with no alteration in the animals’ weight,
we observe that long-term cordycepin administration did not
induce an increase in the levels of alkaline phosphatase (ALP)
(Supplementary Material, Fig. 2C) and alanine aminotransferase
(ALT) (Supplementary Material, Fig. 2D). These results suggest
a strong and safe neuroprotective effect for cordycepin in vivo,
mitigating the neuropathological abnormalities in a lentiviral
MJD mouse model.
Cordycepin treatment improves motor deficits and
neuropathological abnormalities in a MJD transgenic
mouse model
The cerebellum is one of the most affected areas in MJD (27).
Thus, we next investigated the effect of cordycepin treatment in
a MJD transgenic mouse model with cerebellar pathology (29). As
early as 3 weeks of age, this model already displayed cerebellar
atrophy, accompanied by imbalance and gait disturbances. We
began a 6 weeks treatment with cordycepin (IP) in the animals
at 4 weeks of age, where the phenotype and neuropathology
are already installed (17). Every 2 weeks, the animals were
tested for different behavioral tests (Supplementary Material,
Fig. 3). In the rotarod tests, the animals treated with cordycepin
showed an increase in the latency to fall times compared
with control animals, both at constant rod velocity (Fig. 5A)
and with an increasing rod velocity (Fig. 5B). Moreover, the
analysis of the footprint patterns at 6 weeks of treatment
revealed that cordycepin-treated animals displayed smaller
footprint overlap measures (Fig. 5C), as well as a reduction in
the hind base measures (Fig. 5D), compared to control animals.
We also checked for weight gain during the course of treatment,
observing that there were no alterations in body weight upon
cordycepin administration (Supplementary Material, Fig. 4).
Overall, these results show that cordycepin improves motor
coordination and balance, clearly slowing the motor deficits
progression, with no apparent toxicity or side effects. We next
investigated whether the observed improvements in motor
function were correlated with improvements in neuropatho-
logical features. This MJD transgenic mouse model expresses a
mutant form of Atx3 with a haemagglutinin (HA) epitope in the
cerebellar Purkinje cells [(29); Supplementary Material, Fig. 5].
The cordycepin-treated animals showed a significant reduction
in the number of cells with HA aggregates, compared to control
animals (Fig. 5E–K), as well as a significant increase in the total
number of Purkinje cells (Fig. 5L–P). Furthermore, we observed
an increased volume in lobes 4, 5, 6 and 8 of the cerebellum in
treated animals, being this difference statistically significant
in lobe 7 (Fig. 5Q–S). Altogether, these results demonstrate
that cordycepin is able to reduce motor and MJD-related
neuropathological abnormalities, even after the onset of the
disease.
Cordycepin treatment reduces the number of
aggregates in an induced pluripotent stem cells MJD
model
To validate the use of cordycepin in a human model, we tested
the treatment in a human neuronal model derived from induced
pluripotent stem cells (iPSCs) of a MJD patient (4). The cordycepin
treatment led to a significant reduction in the number of ubiq-
uitin aggregates, comparing to a control condition (Fig. 6A–G).
No differences were detected in the alamar test between both
conditions, thus suggesting that cordycepin does not affect cell
proliferation/viability (Fig. 6H). These results confirm the ability
of cordycepin to reduce mutant Atx3 aggregates, with no toxicity
for the cells.
Discussion
MJD is a fatal neurodegenerative disorder that results in serious
clinical complications along with a decline of life quality for
patients suffering from this condition. In the past years, sev-
eral studies reported different therapeutic approaches aiming to
stop or delay disease progression (1,8,19,20,26). Although these
strategies produced encouraging results, currently there are no
available therapeutic approaches for MJD patients.
Recently, we showed that molecular modulation through
LV of mutant Atx3 translation constitutes a new therapeutic
strategy reducing MJD abnormalities (17). Though this strategy
can reach high levels of specificity, it is some steps away
from a translation to human clinics. Aiming a more rapid and
easy translation to the clinics, we investigated a European
Medicines Agency- and Food and Drug Administration-approved
pharmacologic compound—cordycepin—with several action
mechanisms, including translation inhibition in different MJD
models. In this study, we found that cordycepin treatment led
to a significant and specific decrease in mutant Atx3 levels in
an N2A cell model, whereas no alterations were observed in
wild-type Atx3 or in endogenous mouse Atx3 levels. The specific
effect of cordycepin toward mutant Atx3 while preserving wild-
type Atx3 is relevant, as although the Atx3 function is not
fully understood its expression throughout the body suggests
an important biological role (23). Taking into consideration the
promising results obtained in the in vitro experiments, we next
investigated the effect of cordycepin treatment in two MJD
animal models. In the MJD lentiviral mouse model, animals
were injected with LV encoding for mutant Atx3 in the striatum,
leading to expression of the mutant Atx3 protein, the formation
of ubiquitin-positive mutant Atx3 inclusions and to the loss of
neuronal markers (2). Cordycepin treatment led to a reduction
in mutant Atx3 aggregates and soluble protein levels detected
by western blot, as well as a reduction in the number and
size of mutant Atx3 ubiquitinated aggregates, and a significant
preservation of the neuronal marker NeuN, comparing to the
control animals, thus suggesting a neuroprotective role of
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not induce toxicity, as confirmed by no alterations in hepatic
enzyme levels. The levels of ALT and ALP, two biomarkers for
liver damage (10), were not increased in cordycepin-treated
animals compared to wild-type mice, which is in agreement
with a hepatoprotective effect described for cordycepin (5). We
also investigated if cordycepin was able to mitigate disease
impairments in a MJD transgenic mouse model with cerebellar
pathology (29). Cordycepin treatment ameliorated mice motor
coordination and balance, assessed by a significant increase
in the latency to fall in the rotarod tests in treated animals,
compared with the control animals. Moreover, treated mice
also displayed a reduction in the footprint overlap and in
the hind base width measurements, indicating improvements
in gait impairments. These motor improvements were also
accompanied by a significant decrease in the number of
intranuclear inclusions, as well as an increase in the number of
Purkinje cells, upon cordycepin treatment. These results suggest
that cordycepin is able to rescue motor and neuropathological
impairments in a setting where the pathology is already
established. We also tested cordycepin in a human neural model,
differentiated from iPSCs derived from MJD patient fibroblasts
(4). Cordycepin administration led to a significant decrease in
the number of ubiquitin aggregates compared to the control
condition, with no alteration in cell viability. Altogether, these
results suggest that cordycepin treatment might constitute an
effective and safe therapy for MJD.
Cordycepin was previously shown to act as an important
translation inhibitor (31). Thus, we also tried to elucidate the
cordycepin molecular action mechanism behind the mitigation
of Atx3-induced abnormalities. It was hypothesized that
cordycepin could activate AMPK pathway, which enhances
the shutdown of the mTOR signaling pathway thus impacting
autophagy. We found that cordycepin treatment in our cellular
model significantly increased the levels of P-AMPK, which was
accompanied by a reduction in the global translation levels. The
autophagy pathway is crucial for clearance of misfolded proteins
and regulation of protein homeostasis, and it was shown to be
deregulated in polyQ diseases, including MJD (6,16). In fact, we
already showed that autophagy targeting might constitute a
therapeutic option for MJD (15). In this study, our results showed
that cordycepin treatment led to an activation of autophagy in
vitro and in vivo, assessed by the monitorization of LC3B-II and
SQSTM1, two proteins that are degraded in the final stages of
the autophagic process. Accordingly, the detected levels of both
substrates upon cordycepin treatment suggest an activation
of the autophagic pathway, in line with similar studies (3,14).
In fact, the autophagic flux measured by the LC3B-II turnover
assay showed that upon cordycepin administration there was
an increase in the amount of LC3B-II delivered to lysosomes,
compared to the control group. Altogether, these results
clearly demonstrate that cordycepin enhances autophagy.
We further analyzed the P-mTOR levels and P-ULK1 levels
(at Ser555), which were reduced upon cordycepin treatment.
These results suggest an activation of mTOR pathway and an
inhibition of autophagy (11,30), which could indicate that cordy-
cepin is activating autophagy through an independent mTOR
pathway.
Overall, in this study, we report a clear and strong neuropro-
tective effect of cordycepin, mediated by an increase in AMPK
phosphorylated levels, an activation of autophagy and reduction
of mutant protein synthesis (Supplementary Material, Fig. 6).
These results might represent a new option for MJD and other
polyQ diseases, as it could reach human clinics in a shorter frame
than other therapeutic strategies tested until now.
Materials and Methods
In vitro cordycepin treatment
N2A cells and human neural cultures (derived from Induced
pluripotent stem cells) were treated with 20 μm and 200 μm of
cordycepin, respectively.
Animals
Adult C57/BL6 male mice (Charles River Laboratories, Barcelona,
Spain) and 4-week-old transgenic MJD mice (29) were used in
this experiment. Transgenic mice were breed in the animal
house facility of the Centre for Neuroscience and Cell Biology
of the University of Coimbra by backcrossing heterozygous MJD
males with C57BL/6 females. All animals were housed in a
temperature-controlled room maintained on a 12 h light–12 h
dark cycle. Food and water were provided ad libitum. The exper-
iments were carried out in accordance with the European Com-
munity directive (86/609/EEC) for the care and use of laboratory
animals. The researchers received adequate training (FELASA-
certified course) and certification to perform the experiments
from the Portuguese authorities (Direcção Geral de Alimentação e
Veterinária).
Lentiviral vectors
LV encoding for human full-length mutant Atx3Q72 and human
wild-type Atx3 (Atx3-27Q) (2) were produced and quantified
in HEK 293T cells using a four-plasmid system described previ-
ously (24).
Neuroblastoma cells culture, infection and cordycepin
treatment
N2a cells obtained from the American Type Culture Collection
cell biology bank (CCL-131) were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10%
fetal bovine serum (FBS), 100 U/ml penicillin and 100 mg/ml
streptomycin (Gibco) at 37◦C in 5% CO2/air atmosphere. Cells
were plated for infection with lentiviral particles expressing
human full-length mutant Atx3Q72 or human wild-type Atx3-
27Q. The infection was performed with 400 μl of new medium,
8 μg/ml of hexadimethrin bromid (Sigma-Aldrich, St. Loius,
Missouri, USA) and the LV in a total concentration of 10 ng of
p24 antigen per 100 000 cells. The cells were then incubated at
37◦C in 5% CO2/air atmosphere and 8 h post-infection it was
added 600 μl of fresh medium to the cells. Transduced cells were
stored at −80◦C in 10% Dimethyl sulfoxide/90% FBS for posterior
use. For cordycepin (3′-deoxyadenosine, 100 mg/ml in DMSO,
Sigma) treatment, cells were plated and 24 h after were treated
with 20 μm of cordycepin. After 48 h of treatment, cells were
harvested for subsequent western blot analysis.
Translation rate assay
For the assessment of global protein synthesis, we used a previ-
ously described assay based on the incorporation of puromycin
into the polypeptide chain during the translation process (25)
and following the same procedure we used before (17).
Autophagic flux measurement
The autophagic flux was measured through the LC3B turnover
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delivered to the lysosomes (3). For that purpose, the levels of
LC3B-II were measured in the presence and absence of ChQ
(ChQ, Sigma and 100 μm), an inhibitor of autolysosomal degra-
dation. The autophagic flux was calculated by subtracting the
densitometric value of LC3B-II in samples without ChQ (LC3B-
II − ChQ) from the corresponding sample treated with ChQ
(LC3B-II + ChQ) for each condition.
Neural stem cell culture and differentiation
Human neural stem cells (NSCs) derived from iPSCs from MJD
fibroblasts were grown attached to flasks coated with Matrigel
(BD Biosciences, Becton, Dickinson and Company, Franklin
Lakes, New Jersey, USA) as previously described (4). Neural
cultures were obtained by seeding 350 000 NSCs/well in 12 MW
plates with coverslips previously coated with poly-L-lysine
and 1 μg/ml laminin (Sigma) and cultured with differentiation
medium: DMEM-F12 supplemented with 2 μm retinoic acid, 5 μm
forskolin, 2% B27 and 1% penicillin–streptomycin (Gibco, Thermo
Fisher Scientific, Waltham, Massachusetts, USA). Cordycepin was
administered at day 5 of differentiation (200 μm), while the same
volume of DMSO (solvent of cordycepin) was used as a control.
The cells were fixed 48 h after adding the cordycepin/DMSO and
were further processed for immunocytochemistry.
Cell proliferation/viability
The resazurin reduction assay is an accepted method to access
cell viability (21). Briefly, 48 h after cordycepin administration,
NSC cultures were incubated in differentiation medium con-
taining 10% resazurin, at 37◦C for 3 h. Then, the absorbance of
the medium was measured at 570 nm and 600 nm. The cell
viability was calculated as a percentage of the control cells
(incubated with DMSO) by applying the following formula: cell
viability (%) = [absorbance (570 – 600 nm) of treated cells × 100] /
[absorbance (570 – 600 nm) of control cells].
Lentiviral mouse model
For the in vivo injection of LV, concentrated viral stocks encoding
for mutant Atx3 (Atx3Q72) were thawed on ice and resuspended.
Eight-week-old C57/BL6 male mice (Charles River Laboratories)
were anesthetized by administration of a mixture of ketamine
(100 mg/kg, Clorketam 1000, Vétaquinol) with xylazine (10 mg/kg,
Rompun®, Bayer) by IP and stereotaxically injected into the right
hemisphere of the striatum in the following coordinates: antero-
posterior, +0.6 mm; lateral, −1.8 mm; ventral, −3.3 mm; mouth
bar, 0. Viral vectors content was determined by p24 antigen ELISA
(RETROtek, Gentaur, France) and injected at a rate of 0.25 μl/min
(a single 1 μl injection of 400 000 ng) by means of an automatic
injector (Stoelting Co., Wood Dale, IL, USA) into the mouse brain
area through a 34-gauge blunt-tip needle linked to a Hamilton
syringe (Hamilton, Reno, NV, USA). After injection, the syringe
needle was left in place for an additional 5 min to allow the
viral vector diffusion and to minimize backflow. One week post-
stereotaxic injection, the cordycepin treatment began. Treated
animals received an IP 40 μl injection of 20 mg/Kg of cordycepin
(100 mg/mL in DMSO-NaCl 0.1%), whereas a 40 μl injection of
the vehicle (NaCl 0.1%) was administrated to the control group
during 1 week or 4 consecutive weeks.
Transgenic mouse model
A transgenic mouse model for MJD (C57BL/6 background)
expressing the N-terminal-truncated human Atx3 with 69
glutamine repeats together with an N-terminal HA epitope in
cerebellar Purkinje cell, driven by the L7 promoter was used (29).
Animals were divided in two groups: the treated group, which
was administered a daily IP 40 μl injection of growing doses of
cordycepin-NaCl 0.1% (15 mg/Kg in the first week, 20 mg/Kg in
the second week and then 25 mg/Kg until the end of experiment),
and the control group, which was injected with 40 μl of the
vehicle solution (NaCl 0.1%). The treatment was maintained for
6 weeks and both groups included female and male mice in the
same proportion.
Behavioral assessment
Transgenic mice groups were subjected to different motor tests
(rotarod and footprint pattern analysis), every 2 weeks from the
first treatment until the end of the experiment. An experienced
operator performed the tests blindly, following the same proce-
dure described before (20). All tests were performed in the same
room after 1 h of acclimatization.
Tissue preparation
For the immunohistochemical procedures, animals received
a sodium pentobarbital overdose, followed by a transcar-
dial perfusion with 0.1 M phosphate buffer solution and a
4% paraformaldehyde fixative solution (Fluka, Sigma, Sigma-
Aldrich, St. Louis, Missouri, USA). The brains were then removed,
post-fixed in 4% paraformaldehyde for 24 h and cryoprotected
by incubation in 25% sucrose/phosphate buffer for 48 h.
Subsequently, brains were frozen and sectioned using a cryostat
(LEICA CM3050 S). For the lentiviral mouse model, coronal
sections of 20 μm were obtained, while for the transgenic
mice, 35 μm sagittal brain sections were made. After sectioning,
brain sections were collected and stored in 48-well trays, free-
floating in 0.1 M phosphate buffer solution supplemented with
0.05 μm sodium azide and stored at 4◦C until further usage. For
western blot analysis, animals were sacrificed through sodium
pentobarbital overdose without transcardial perfusion. Animals’
blood was collected and sent to a clinical and pathological
analyses laboratory for analyses of the hepatic enzymes: ALT
and ALP. Brains were removed and dissected fresh for collection
of striatal punches using a Harris Uni-Core pen, with 2.0 mm
diameter (Ted Pella Inc., Redding, California, USA). Brain punches
samples were then stored at −80◦C until posterior processing.
Western blot
For protein extraction, brain tissue or cells were first lysed in
RIPA-buffer solution (50 mm Tris HCl pH = 8; 150 nm NaCl; 1%
NP-40; 0.5% sodium deoxycholate; 0.1% SDS) containing protease
inhibitors (Roche diagnostics, Risch-Rotkreuz, Switzerland),
followed by sonication of 4 s ultrasound chase (1 pulse/s). Total
protein lysates were stored at −80◦C and protein concentration
was determined through the PierceTM BCA Protein Assay
Kit (Thermo Scientific, Thermo Fisher Scientific, Waltham,
Massachusetts, USA). Sixty micrograms of protein extract
were resolved in SDS-polyacrylamide gels (10%). Then proteins
were transferred onto polyvinylidene difluoride membrane
(GE Healthcare) according to standard protocols. Immunoblot-
ting was performed using the following antibodies: mouse
monoclonal anti-Atx3 (Millipore, 1:1000), mouse anti-tubulin
(Sigma; 1:5000), anti-AMPK (1:1000, Cell Signaling), anti-phospho-
AMPK (1:2000, Cell Signaling), rabbit anti-mTOR (1:1000; Cell
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rabbit anti-ULK1 (1:1000; Cell Signaling), rabbit anti-phospho-
ULK1 (Ser555) (1:1000; Cell Signaling), rabbit anti-LC3B (1:1000,
Cell Signaling), rabbit anti-SQSTM1 (1:1000, Cell Signaling),
mouse anti-puromycin (Millipore, 1:20000) and mouse anti-
GAPDH (1:3000; Abcam). Semi-quantitative analysis was carried
out based on the optical density of the same gel (Quantity One®1-
D image analysis software version 4.4; Bio-Rad).
Immunochemical procedures
Immunocytochemistry. Immunocytochemistry was performed
based on protocols described previously (13,17). Briefly, cells
were washed with Phosphate-buffered saline and fixed with
4% paraformaldehyde (Sigma) at room temperature for 15 min.
The cells were then permeabilized with 1% TritonTM X-100
(Sigma) followed by 1 h of blocking with 3% Bovine Serum
Albumin (Sigma) in PBS. The primary antibodies were incubated
with cells overnight at 4◦C. Cells were then washed with PBS
following incubation with the secondary antibodies for 2 h at
room temperature. Subsequently, cells were washed with PBS
and nuclei were stained with 4′,6′-Diamidino-2′-phenylindole
(1:5000, Applichem) for 5 min at room temperature. After a
washing step, the coverslips were mounted on microscope slides
using Mowiol as a mounting medium. Images were acquired
with 20× objective in a Zeiss Axio Imager Z2.
Immunohistochemistry. Immunocytochemistry assay was per-
formed as previously described (18,19). Briefly, the immunohisto-
chemistry for light microscopy began by incubating free floating
the brain slices in phosphate buffer solution containing 0.1%
diphenylhydrazine for 1 h at 37◦C. Sections were then incubated
in blocking solution [0.1% TritonX 100 containing 10% Normal
Goat Serum (NGS, Gibco) in phosphate buffer solution], followed
by overnight incubation at 4◦C with respective primary antibod-
ies. Posteriorly, sections were incubated with secondary antibody
for 2 h at room temperature. The secondary antibody (1:200) used
was biotinylated and followed a reaction with the Vectastain
elite avidin-biotin-peroxidase kit and by 3,3′-diaminobenzidine
substrate (both from Vector Laboratories). Sections were then
mounted over microscope slides, hydrated with H2O and then
dehydrated by passing through an increased degree of ethanol
solutions (ETOH 75, 96 and 100%) and finally xylene. Slides were
covered with mounting medium Eukitt (O. Kindler GmbH &
CO, Freiburg, Germany) and coverslipped. In the fluorescence-
labeling protocol, sections were incubated in a 0.3% Triton 10%
NGS 0.1 phosphate buffer blocking solution for 1 h at room
temperature and then overnight at 4◦C with the appropriate
primary antibodies. Afterwards, slices were incubated in the sec-
ondary antibody for 2 h at room temperature. Sections were then
incubated with DAPI solution (1:5000) for 10 min at room temper-
ature, washed and mounted on Mowiol mounting medium.
Immunochemical antibodies. Samples were incubated with
the following primary antibodies: mouse anti-β III tubu-
lin (1:500, Invitrogen, Thermo Fisher Scientific, Waltham,
Massachusetts, USA), rabbit anti-ubiquitin (1:300, Enzo Life Sci-
ences, Farmingdale, New York, USA), anti-ubiquitin (1:500; Merck
Millipore, Burlington, Massachusetts, USA), anti-NeuN (1:1000,
Chemicon International, Thermo Fisher Scientific, Waltham,
Massachusetts, USA), anti-HA (HA tag, 1:1000, InvivoGen, San
Diego, California, USA) and anti-Calbindin (clone D-28 K, 1:1000,
Chemicon).
Cresyl violet staining
Brain slices were mounted over microscope slides, stained
with cresyl violet dye and dehydrated by passing through an
increased degree of ethanol solutions (ETOH 75, 96 and 100%)
and finally xylene. Slides were then covered with mounting
medium Eukitt (O. Kindler GmbH & CO, Freiburg, Germany) and
cover slipped.
Immunochemistry quantitative analysis
Evaluation of the NeuN depleted volume. The extent of neuronal
lesion in the striatum was photographed, with a 20× objec-
tive, eight sections per animal (20 μm thickness sections at
200 μm intervals) stained with the neuronal marker NeuN, thus
obtaining a complete rostrocaudal sampling of the striatum. A
semi-automated image analysis software package was used to
measure the area of the neuronal lesion (Image J software, USA).
The final depleted volume was then estimated with the follow-
ing formula: volume = d∗(a1 + a2 + a3), where d is the distance
between serial sections (200 μm) and a1 + a2 + a3 are depleted
areas for individual serial sections. Data are represented as mean
value of the final NeuN depleted volume of the eight sections
relative to the striatum total volume.
Quantification of ubiquitin inclusions number and size. Coronal
sections for a complete rostrocaudal sampling (eight sections)
of the striatum were scanned with a 20× objective using a Zeiss
Axiovert 200 M imaging microscope Zeiss (Zeiss, Germany), thus
including regions with ubiquitin-positive aggregates. For each
animal, all inclusions were manually counted using a semi-
automated image-analysis software package (Image J software,
USA). The size of the aggregates was automatically counted
using the CellProfiler software.
Quantification of mutant Atx3 aggregates and Purkinje cells..
Fluorescence images of 8 sagittal sections, spanning 280 μm
between them, of the entire cerebellum, stained with anti-
HA, anti-Calbindin and DAPI were acquired with a Zeiss Axio
Imager Z2 microscope using a 20× objective. For each section, the
number of cells with mutant Atx3 aggregates and Purkinje cells
were manually counted in all cerebellar lobules using an image
analysis software (ZEN 2.1 lite, Zeiss). Data are represented as
mean value of the number of cells with aggregates of the eight
sections analyzed or the number of Purkinje cells normalized
with the number of aggregates per section.
Quantification of cerebellar lobular volume. Fluorescence images
of eight sagittal sections, spanning 280 μm between them, of
the entire cerebellum, stained with cresyl violet were acquired
with a Zeiss Axio Imager Z2 microscope using a 20× objective.
For each section, the area of each cerebellar lobe was measured
using an image analysis software (ZEN 2.1 lite, Zeiss). The final
lobe volume was then estimated with the following formula:
volume = d∗(a1 + a2 + a3), where d is the distance between
serial sections (280 μm) and a1 + a2 + a3 are lobe areas for
individual serial sections. Data are represented as mean value
of the cerebellar lobe volume of the eight sections analyzed
normalized with cerebellum total volume.
Statistical analysis. Statistical analysis was performed using
Student’s t-test or ANOVA for multiple comparisons using
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